(firstQuint)CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma.

 A prospective study to evaluate the safety and efficacy of CART19 for refractory/relapsed B cell lymphoma.

 Complete remission rate, overall survival rate, relapse rate and CRS rate were monitored.

 CART associated toxicities were also monitored.

.

 CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma@highlight

A prospective study to evaluate the safety and efficacy of CART19 for refractory/relapsed B cell lymphoma.

